Based on current evidence, this guideline addresses important clinical questions regarding biologic agents used as monotherapy or in combination with other psoriasis therapies to treat …

With the progressive aging of the population, a growing number of patients with psoriasis can be expected to present multiple comorbidities. Currently, there is a wide range of biological …

Doctors often use biologic drugs on people with moderate to severe psoriasis. Moderate psoriasis means that 3% to 10% of your body is covered with red, scaly patches.

May 6, 2025 · Why carry out this study? Moderate-to-severe plaque psoriasis is a chronic, immune-mediated condition that can be treated with biologic therapies. Comparisons of …

Mar 24, 2025 · Often, they are indicated for moderate to severe plaque psoriasis but may include other types of psoriasis and PsA. Your health care provider can help determine if biologics are …

Oct 31, 2025 · Results of a meta-analysis showed that all biologic agents were superior to placebo for improving short-term outcomes in moderate to severe plaque psoriasis.

Dec 28, 2024 · Biologics are administered via subcutaneous injection or intravenous infusion and are reserved for moderate to severe cases of psoriasis. Other biologic drugs include tumor …

Nov 12, 2025 · Treatment Selection Based on Disease Severity For mild psoriasis (<5% body surface area), start with topical corticosteroids combined with vitamin D analogs as first-line …

Jun 16, 2025 · Article highlights IL-23 inhibitors (guselkumab, risankizumab, and tildrakizumab) are the most recent class of biologics approved for moderate-to-severe plaque psoriasis. Real …

The newest biologic agents for plaque psoriasis are the IL-17 and IL-23 inhibitors, both of which were discussed at the 2024 Fall Clinical Dermatology Conference. The most recent US Food …